Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Exploring the dual role of nirmatrelvir and bisphosphonates in COVID-19 treatment and immunity

Review examines nirmatrelvir and bisphosphonates in treating COVID-19, revealing their impact on SARS-CoV-2-specific adaptive immunity and potential to mitigate severe infections, highlighting the need for balanced long-term immunity management.

16 Nov 2023

One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals

The frequency of viral rebound (VR) among acute coronavirus disease 2019 patients.

16 Nov 2023

Study observes virologic rebound in 20% of COVID-19 patients treated with nirmatrelvir-ritonavir

An observational study of patients being treated for acute COVID-19 in a multicenter health care system observed virologic rebound in about 20 percent of patients treated with nirmatrelvir-ritonavir (N-R) versus about 2 percent of those who did not receive treatment. The findings are published in Annals of Internal Medicine.

13 Nov 2023

One in five individuals taking nirmatrelvir-ritonavir therapy found to experience rebound COVID

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test-;a phenomenon known as virologic rebound.

13 Nov 2023

WHO experts update guidance on COVID-19 treatments

A panel of international experts representing the World Health Organization's Guideline Development Group has updated its guidance on treatments for patients with covid-19.

9 Nov 2023

Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited.

24 Oct 2023

Paxlovid treatment provides protection against COVID-19 for both mother and child

A new mouse model of infection with the COVID-19-causing SARS-CoV-2 virus during pregnancy tracks closely the disease course doctors have observed in SARS-CoV-2-infected pregnant patients, and suggests that treatment with the antiviral Paxlovid provides protection for both mother and child.

16 Oct 2023

Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups

Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study. However, the treatment's efficacy varied based on the degree of vulnerability, emphasizing tailored approaches for different risk groups.

8 Oct 2023

NIH launches and opens enrollment for phase 2 clinical trials to evaluate long COVID treatments

Today, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months.

31 Jul 2023

Oral antivirals Molnupiravir and Nirmatrelvir-Ritonavir lower COVID-19 risks in type 2 diabetes patients

Research investigates the effectiveness of oral antiviral medications, Molnupiravir and Nirmatrelvir-Ritonavir, in treating patients with type 2 diabetes and mild to moderate COVID-19. The study aims to determine the efficacy of these medications in reducing adverse outcomes in this specific population.

24 May 2023

Nanoparticles take aim at COVID-19 with lysosome-targeted delivery

Researchers discuss the use of endo-lysosome-targeted nanoparticles for delivering antiviral therapy to treat coronavirus infections.

15 May 2023

Nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization

Researchers assess whether nirmatrelvir/ritonavir treatment reduced the risk of COVID-19-related hospitalization.

10 May 2023

Molnupiravir treatment reduces risk of long COVID in high risk patients

Among high-risk individuals, molnupiravir treatment in the acute phase of infection could prevent long COVID.

27 Apr 2023

Nirmatrelvir-ritonavir reduces risk of post-COVID syndrome in non-hospitalized vaccinated patients

Researchers assess the effect of nirmatrelvir plus ritonavir on the occurrence of long COVID.

12 Apr 2023

Is nirmatrelvir treatment of SARS-CoV-2 associated with a lower risk of post–COVID-19 condition?

Researchers performed an observational cohort study using the US Department of Veterans Affairs healthcare databases.

27 Mar 2023

Higher Paxlovid uptake in winter 2022 could have prevented nearly 5,000 deaths

In a recent study published in the JAMA Health Forum, researchers in the United States estimated the reduction in coronavirus disease 2019 (COVID-19) mortality rates after the Paxlovid rollout.

22 Mar 2023

Study reveals why COVID-19 subvariants spread rapidly among previously infected people

The COVID-19 pandemic has killed nearly 7 million people worldwide (1.1 million in the United States) and severely harmed many millions more, though vaccines and antiviral treatments measurably reduced the potential loss of life and health.

22 Mar 2023

Paxlovid is 80% effective when taken within 5 days of severe COVID

In a recent study published in The Lancet’s Infectious Diseases, researchers in the United States evaluated nirmatrelvir–ritonavir treatment effectiveness against hospitalizations and deaths among coronavirus disease 2019 (COVID-19) outpatients in the United States of America (USA).

21 Mar 2023

Study confirms the benefit of Paxlovid as an early-stage treatment to prevent COVID-19 hospitalization

A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age.

17 Mar 2023

AI-based drug interaction prediction technology analyzes the interaction between Paxlovid ingredients

KAIST (President Kwang Hyung Lee) announced on the 16th that an advanced AI-based drug interaction prediction technology developed by the Distinguished Professor Sang Yup Lee's research team in the Department of Biochemical Engineering that analyzed the interaction between the PaxlovidTM ingredients that are used as COVID-19 treatment and other prescription drugs was published as a thesis.

16 Mar 2023